Literature DB >> 7619525

Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain.

J Näslund1, J Thyberg, L O Tjernberg, C Wernstedt, A R Karlström, N Bogdanovic, S E Gandy, L Lannfelt, L Terenius, C Nordstedt.   

Abstract

Genetic evidence suggests a role for apolipoprotein E (apoE) in Alzheimer's disease (AD) amyloidogenesis. Here, amyloid-associated apoE from 32 AD patients was purified and characterized. We found that brain amyloid-associated apoE apparently exists not as free molecules but as complexes with polymers of the amyloid beta peptide (A beta). Brain A beta-apoE complexes were detected irrespective of the apoE genotype, and similar complexes could be mimicked in vitro. The fine structure of purified A beta-apoE complexes was fibrillar, and immunogold labeling revealed apoE immunoreactivity along the fibrils. Thus, we conclude that A beta-apoE complexes are principal components of AD-associated brain amyloid and that the data presented here support a role for apoE in the pathogenesis of AD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619525     DOI: 10.1016/0896-6273(95)90079-9

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  57 in total

1.  Apolipoprotein E forms stable complexes with recombinant Alzheimer's disease beta-amyloid precursor protein.

Authors:  C Haas; P Cazorla; C D Miguel; F Valdivieso; J Vázquez
Journal:  Biochem J       Date:  1997-07-01       Impact factor: 3.857

2.  Presenilin-1 is associated with Alzheimer's disease amyloid.

Authors:  T Wisniewski; W K Dowjat; B Permanne; J Palha; A Kumar; G Gallo; B Frangione
Journal:  Am J Pathol       Date:  1997-08       Impact factor: 4.307

3.  Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease.

Authors:  Martin J Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; Pankaj D Mehta; Frances Prelli; David Quartermain; Thomas Wisniewski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-20       Impact factor: 11.205

Review 4.  The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease.

Authors:  Sam Gandy
Journal:  J Clin Invest       Date:  2005-05       Impact factor: 14.808

5.  Lipocalin-type prostaglandin D synthase/beta-trace is a major amyloid beta-chaperone in human cerebrospinal fluid.

Authors:  Takahisa Kanekiyo; Tadato Ban; Kosuke Aritake; Zhi-Li Huang; Wei-Min Qu; Issay Okazaki; Ikuko Mohri; Shigeo Murayama; Keiichi Ozono; Masako Taniike; Yuji Goto; Yoshihiro Urade
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-02       Impact factor: 11.205

Review 6.  Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease.

Authors:  Evan Dorey; Nina Chang; Qing Yan Liu; Ze Yang; Wandong Zhang
Journal:  Neurosci Bull       Date:  2014-03-20       Impact factor: 5.203

7.  A flow cytometry-based in vitro assay reveals that formation of apolipoprotein E (ApoE)-amyloid beta complexes depends on ApoE isoform and cell type.

Authors:  Eleanna Kara; Jordan D Marks; Allyson D Roe; Caitlin Commins; Zhanyun Fan; Maria Calvo-Rodriguez; Susanne Wegmann; Eloise Hudry; Bradley T Hyman
Journal:  J Biol Chem       Date:  2018-06-27       Impact factor: 5.157

8.  Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease.

Authors:  C Russo; G Angelini; D Dapino; A Piccini; G Piombo; G Schettini; S Chen; J K Teller; D Zaccheo; P Gambetti; M Tabaton
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

9.  Role of Apolipoprotein E in β-Amyloidogenesis: ISOFORM-SPECIFIC EFFECTS ON PROTOFIBRIL TO FIBRIL CONVERSION OF Aβ IN VITRO AND BRAIN Aβ DEPOSITION IN VIVO.

Authors:  Yukiko Hori; Tadafumi Hashimoto; Hidetoshi Nomoto; Bradley T Hyman; Takeshi Iwatsubo
Journal:  J Biol Chem       Date:  2015-04-27       Impact factor: 5.157

10.  A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice.

Authors:  Marcin Sadowski; Joanna Pankiewicz; Henrieta Scholtzova; James A Ripellino; Yongsheng Li; Stephen D Schmidt; Paul M Mathews; John D Fryer; David M Holtzman; Einar M Sigurdsson; Thomas Wisniewski
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.